EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Improving the future of clinical trials and translation of mesenchymal stromal cell therapies for neonatal disorders

Yun Sil Chang, Misun Yang iD, So Yoon Ahn, Se In Sung, Won Soon Park

Stem Cells Translational Medicine · 2024

DOI: 10.1093/stcltm/szae060 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Stem Cells Translational Medicine, 2024. Verfasst von Yun Sil Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Mesenchymal Stem Cell Transplantation, Clinical Trials as Topic, Mesenchymal Stem Cells. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Samsung Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite recent advances in neonatal intensive care medicine, neonatal disorders such as (bronchopulmonary dysplasia [BPD], intraventricular hemorrhage [IVH], and hypoxic ischemic encephalopathy [HIE]) remain major causes of death and morbidity in survivors, with few effective treatments being available. Recent preclinical studies have demonstrated the pleiotropic host injury-responsive paracrine protective effects of cell therapy especially with mesenchymal stromal cells (MSCs) against BPD, IVH, and HIE. These findings suggest that MSCs therapy might emerge as a novel therapeutic modality for these currently devastating neonatal disorders with complex multifactorial etiologies. Although early-phase clinical trials suggest their safety and feasibility, their clinical therapeutic benefits have not yet been proven. Therefore, based on currently available preclinical research and clinical trial data, we focus on critical issues that need to be addressed for future successful clinical trials and eventual clinical translation such as selecting the right patient and optimal cell type, route, dose, and timing of MSCs therapy for neonatal disorders such as BPD, HIE, and IVH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem Cell TransplantationClinical Trials as TopicMesenchymal Stem CellsHumansInfant, NewbornAnimalsBronchopulmonary DysplasiaHypoxia-Ischemia, BrainInfant, Newborn, DiseasesTranslational Research, Biomedical

Stichwörter der Autor:innen

bronchopulmonary dysplasiacell therapydiseaseshypoxic ischemic encephalopathyintraventricular hemorrhagemesenchymal stromal cellsneonataltranslational medicine

Autor:innen und Institutionen

  • Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul, Korea.
  • Cell and Gene Therapy Institute, Samsung Medical Center, Seoul, Korea.
  • Department of Pediatrics, Gangnam Cha Hospital, Cha University, Seoul, Korea.

ORCID-Profile: Misun Yang

Förderung

  • Samsung Medical Center

Zitieren

APA

Chang, Y. S., Yang, M., Ahn, S. Y., Sung, S. I., & Park, W. S. (2024). Improving the future of clinical trials and translation of mesenchymal stromal cell therapies for neonatal disorders. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szae060

Vancouver

Chang YS, Yang M, Ahn SY, Sung SI, Park WS. Improving the future of clinical trials and translation of mesenchymal stromal cell therapies for neonatal disorders. Stem Cells Translational Medicine. 2024. doi:10.1093/stcltm/szae060

BibTeX
@article{Chang2024,
  author = {Chang, Yun Sil and Yang, Misun and Ahn, So Yoon and Sung, Se In and Park, Won Soon},
  title = {Improving the future of clinical trials and translation of mesenchymal stromal cell therapies for neonatal disorders},
  journal = {Stem Cells Translational Medicine},
  year = {2024},
  doi = {10.1093/stcltm/szae060}
}
Kostenlos starten →